Sort   by:  
 Page size 
UnknownPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Not available
S-EPMC3804291 | biostudies-literature
UnknownCCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies.
Not available
S-EPMC6544928 | biostudies-literature
UnknownSafety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Not available
S-EPMC4878046 | biostudies-literature
UnknownActinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway.
Not available
S-EPMC6890794 | biostudies-literature
UnknownPhase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
Not available
S-EPMC10632668 | biostudies-literature
UnknownObesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Not available
S-EPMC10932613 | biostudies-literature
UnknownRadiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Not available
S-EPMC6319250 | biostudies-literature
UnknownReduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Not available
S-EPMC7362362 | biostudies-literature
UnknownActive symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
Not available
S-EPMC2431123 | biostudies-literature
Sort   by:  
 Page size